Elisabetta Cariani

Dr. Elisabetta Cariani

Toxicology and Advanced Diagnostics, Ospedale S. Agostino-Estense, Modena, Italy

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1988 in Cancer
Verified
Journal Article
Closed access
PDF file
Erica VillaErica Villa
Erica Villa
GBGrazia M. Baldini
Grazia M. Baldini
CPClaudio Pasquinelli
Claudio Pasquinelli
MMMargherita Melegari
Margherita Melegari
Elisabetta CarianiElisabetta Cariani
Elisabetta Cariani
FMFederico Manenti
Federico Manenti

1 October 1991 in Journal of Virological Methods
Verified
Journal Article
Closed access
LILuisa Imberti
Luisa Imberti
Elisabetta CarianiElisabetta Cariani
Elisabetta Cariani
ABAlessandra Bettinardi
Alessandra Bettinardi
AZAntonella Zonaro
Antonella Zonaro
AAAlberto Albertini
Alberto Albertini
DPDaniele Primi
Daniele Primi


1 October 1992 in Hepatology
Verified
Journal Article
Open access
PDF file
Massimo PuotiMassimo Puoti
Massimo Puoti
AZAntonella Zonaro
Antonella Zonaro
ARAntonella Ravaggi
Antonella Ravaggi
MMMaria Grazia Marin
Maria Grazia Marin
FCFilippo Castelnuovo
Filippo Castelnuovo
Elisabetta CarianiElisabetta Cariani
Elisabetta Cariani
: Hepatitis C virus RNA, anti—hepatitis C virus immune response and biochemical markers of liver injury were investigated in 17 patients with acute non–A, non–B hepatitis. At the first observation, 1 to 3 wk from the clinical onset, all patients had hepatitis C virus RNA in their serum, and most (15 of 17) were positive for second–generation anti—hepatitis C virus enzyme immunoassay. Follow–up serum samples were available for 10 patients. The rate of recombinant immunoblot assay—confirmed anti—hepatitis C virus enzyme immunoassay reactivities increased from 67% in the first 3 wk to 86% after 21 wk. Elevated ALT levels were associated with hepatitis C virus RNA positivity in most of cases, but the viral nucleic acid was also detected in sera with normal or slightly increased enzyme values. None of the single antibodies tested were related to hepatitis C virus RNA positivity or to the clinical phase of the infection. Therefore hepatitis C virus RNA determination might provide important additional information as compared with anti—hepatitis C virus markers, allowing earlier diagnosis, discrimination of active infection and, possibly, prognostic evaluation. (HEPATOLOGY 1992;16:877-881.)

2 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Elisabetta CarianiElisabetta Cariani
Elisabetta Cariani
MPMassimo Pilli
Massimo Pilli
AZAlessandro Zerbini
Alessandro Zerbini
CRCristina Rota
Cristina Rota
AOAndrea Olivani
Andrea Olivani
GMGabriele Missale
Gabriele Missale
The definition of the risk of hepatocellular carcinoma (HCC) recurrence after resection represents a central issue to improve the clinical management of patients. In this study we examined the prognostic relevance of infiltrating immune cell subsets in the tumor (TIL) and in nontumorous (NT) liver (LIL), and the expression of immune-related and lineage-specific mRNAs in HCC and NT liver derived from 42 patients. The phenotype of infiltrating cells was analyzed by flow cytometry, and mRNA expression in liver tissue was examined by real-time reverse transcription (RT)-PCR. The tumor immune microenvironment was enriched in inhibitory and dysfunctional cell subsets. Enrichment in CD4+ T-cells and in particular CD4 and CD8+ memory subsets within TIL was predictive of better overall survival (OS) and time to recurrence (TTR). Increased programmed death ligand 1 (PDL1) mRNA content and higher prevalence of invariant NKT (iNKT) cells were associated with shorter OS and TTR, respectively. By combined evaluation of infiltrating cell subsets along with mRNA profiling of immune and tumor related genes, we identified the intratumoral frequency of memory T-cells and iNKT-cells as well as PDL1 expression as the best predictors of clinical outcome. HCC infiltrate is characterized by the expression of molecules with negative regulatory function that may favor tumor recurrence and poor survival.

1 December 1988
Verified
Journal Article
Closed access
Elisabetta CarianiElisabetta Cariani
Elisabetta Cariani
CLC LASSERRE
C LASSERRE
DSD SEURIN
D SEURIN
BHB HAMELIN
B HAMELIN
FKF KEMENY
F KEMENY
CBC BRECHOT
C BRECHOT